PLB Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alexidine dihydrochloride | 1715-30-6 | sc-210775A sc-210775 | 100 mg 1 g | $116.00 $464.00 | 7 | |
Alexidine dihydrochloride exhibits distinctive properties as a potent antimicrobial agent, characterized by its dual-targeting mechanism that disrupts microbial membrane integrity. Its cationic nature facilitates strong electrostatic interactions with negatively charged phospholipids, leading to membrane destabilization. The compound's hydrophobic regions enhance penetration into lipid bilayers, while its rapid adsorption kinetics contribute to effective microbial inhibition. This unique behavior underscores its role in modulating cellular environments. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol is a non-selective beta-adrenergic receptor blocker with alpha-blocking activity. It inhibits protein kinase A (PKA) phosphorylation of phospholamban (PLB), leading to increased calcium uptake by the sarcoplasmic reticulum in cardiomyocytes. | ||||||
Enoximone | 77671-31-9 | sc-252775 sc-252775A | 10 mg 50 mg | $181.00 $728.00 | 1 | |
Enoximone, another PDE3 inhibitor, increases cAMP levels, resulting in PKA-mediated phosphorylation of PLB. This phosphorylation enhances the uptake of calcium by the sarcoplasmic reticulum in cardiomyocytes. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective PDE4 inhibitor. By elevating cAMP levels, it indirectly promotes PLB phosphorylation by PKA, which enhances calcium transport into the sarcoplasmic reticulum in cardiac cells. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol is a PDE3 inhibitor that increases cAMP levels. This elevation in cAMP activates PKA, leading to phosphorylation of PLB and improved calcium uptake by the sarcoplasmic reticulum in the heart. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is a calcium channel blocker that reduces calcium influx into cardiomyocytes. It indirectly affects PLB phosphorylation by modulating intracellular calcium levels, which can influence the activity of calcium-dependent enzymes like PKA. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem, like verapamil, is a calcium channel blocker. By decreasing calcium entry into cardiac cells, it impacts intracellular calcium levels, which in turn can influence PKA-mediated PLB phosphorylation and calcium handling. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a dihydropyridine calcium channel blocker, reduces calcium influx into cardiomyocytes. Its effect on calcium levels indirectly affects PKA-mediated phosphorylation of PLB and subsequent calcium transport in the heart. | ||||||